SoftBank’s Vision Fund 2 has taken part in a series D round for Lumicks, which is developing single-molecule analysis technology.
Netherlands-based single-molecule analysis technology developer Lumicks has closed a $93m series D round backed by internet and telecommunications group SoftBank’s Vision Fund 2.
The round was co-led by Farallon Capital Management and Lauxera Capital Partners and included funds and accounts advised by T Rowe Price, Parian Global Management, Pura Vida Investments, Irving Investors, existing backer Gilde Healthcare and unnamed members of Lumicks’ management team.
Lumicks is developing single-molecule analysis technology for molecular biology research and immunotherapy development. Its tools include…
